中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

40 records (took 0.035 seconds)

    Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
    2.
    发明授权
    Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides 有权
    表达MPHOSPH1或DEPDC1多肽的癌症疫苗

    公开(公告)号：US09545437B2

    公开(公告)日：2017-01-17

    申请号：US14667560

    申请日：2015-03-24

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Tomoaki Fujioka ,  Yusuke Nakamura ,  Takuya Tsunoda ,  Ryuji Osawa ,  Midori Shida

    IPC: A61K39/00

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/54 ,  A61K2039/55566 ,  A61K2039/57 ,  A61K2039/572 ,  C07K7/06 ,  C07K14/4703

    Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 7, 8, 9, 10, 11, 12, 192, 195, 197, 209, 225, 226, 228, 230, 240, 241, 243, 244, 249, 253, 254 or 255, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, wherein the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with the over-expression of MPHOSPH1 and/or DEPDC1, e.g. cancers, containing these peptides as an active ingredient. The peptides of the present invention can also be used as vaccines.

    Abstract translation: 本发明提供具有如SEQ ID NO：7,8,9,10,11,12,192,195,197,209,225,226,228,230,240,241,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,29,2 243,244,249,253,254或255，以及具有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失或加入，其中肽具有细胞毒性T细胞诱导性 。 本发明还提供用于治疗或预防与MPHOSPH1和/或DEPDC1的过度表达相关的疾病的药物，例如， 含有这些肽作为活性成分的癌症。 本发明的肽也可以用作疫苗。

    Melk epitope peptides and vaccines containing the same
    3.
    发明授权
    Melk epitope peptides and vaccines containing the same 有权
    Melk表位肽和含有它们的疫苗

    公开(公告)号：US09193765B2

    公开(公告)日：2015-11-24

    申请号：US14171532

    申请日：2014-02-03

    Applicant: Oncotherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa

    IPC: C07K14/00 ,  C07K7/06 ,  C07K14/47 ,  A61K38/00 ,  A61K39/00

    CPC classification number: A61K39/0011 ,  A61K38/00 ,  A61K39/00 ,  A61K2039/5158 ,  C07K7/06 ,  C07K14/4747 ,  C12N5/0638 ,  C12N9/12 ,  C12N2502/11 ,  C12N2510/00 ,  C12Y207/10002 ,  C12Y207/11001

    Abstract: According to the present invention, peptides having the amino acid sequence of SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62 were demonstrated to have cytotoxic T lymphocyte (CTL) inducibility. Therefore, the present invention provides a peptide having the amino acid sequence selected from among SEQ ID NOs: 14, 21, 23, 27, 36, 46, 57, 60 and 62. The peptide can include one, two, or several amino acid substitutions, deletions, insertions, or additions so long as its CTL inducibility is retained. Furthermore, the present invention provides pharmaceutical agents for the treatment and/or prophylaxis of cancers, and/or prevention of postoperative recurrence thereof, which contain any of these peptides. Pharmaceutical agents of this invention include vaccines.

    Abstract translation: 根据本发明，具有SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽被证明具有细胞毒性T淋巴细胞（CTL）诱导性。 因此，本发明提供了具有选自SEQ ID NO：14,21,23,27,36,46,57,60和62的氨基酸序列的肽。肽可以包括一个，两个或几个氨基酸 取代，缺失，插入或添加，只要其CTL诱导性得以保留即可。 此外，本发明提供了用于治疗和/或预防癌症的药物和/或预防其术后复发，其含有任何这些肽。 本发明的药剂包括疫苗。

    METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES
    4.
    发明申请
    METHOD OF INDUCING AN IMMUNE RESPONSE BY ADMINISTERING WDRPUH EPITOPE PEPTIDES 审中-公开
    通过管理WDRPUH EPITOPE肽诱导免疫应答的方法

    公开(公告)号：US20150315239A1

    公开(公告)日：2015-11-05

    申请号：US14805424

    申请日：2015-07-21

    Applicant: ONCOTHERAPY SCIENCE, INC.

    Inventor： Takuya Tsunoda ,  Ryuji Ohsawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: C07K7/06 ,  A61K39/00

    CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/1764 ,  A61K39/0011 ,  C07K14/47 ,  C07K14/4748 ,  C12N5/0638 ,  C12N5/0639

    Abstract: The present invention provides peptides containing the amino acid sequence of SEQ ID NOs: 1, 2, 3, 4, 16, 17, 30, 31, 34, 36, 37, 40, 41, 45, 49, 55, 57 and 61, as well as peptides containing the above-mentioned amino acid sequences in which 1, 2, or several amino acid(s) are substituted, deleted, inserted or added, but still have cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors, which drugs containing these peptides. The peptides of the present invention can also be used as vaccines.

    Abstract translation: 本发明提供了含有SEQ ID NO：1,2,3,4，16，17，30，31，34，36，37，40，41，45，49，55，57和61的氨基酸序列的肽 ，以及含有上述氨基酸序列的肽，其中1,2或几个氨基酸被取代，缺失，插入或添加，但仍具有细胞毒性T细胞诱导性。 本发明还提供了用于治疗或预防肿瘤的药物，其含有这些肽的药物。 本发明的肽也可以用作疫苗。

    UBE2T peptides and vaccines containing the same
    6.
    发明授权
    UBE2T peptides and vaccines containing the same 有权

    公开(公告)号：US11266729B2

    公开(公告)日：2022-03-08

    申请号：US16120102

    申请日：2018-08-31

    Applicant: OncoTherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: A61K39/00 ,  C12N5/0783 ,  C12N5/078 ,  C07K16/40 ,  A61K31/7088 ,  C12N9/00 ,  G01N33/574

    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

    UBE2T peptides and vaccines containing the same
    9.
    发明授权
    UBE2T peptides and vaccines containing the same 有权

    公开(公告)号：US10092634B2

    公开(公告)日：2018-10-09

    申请号：US14400169

    申请日：2013-09-09

    Applicant: OncoTherapy Science, Inc.

    Inventor： Takuya Tsunoda ,  Ryuji Osawa ,  Sachiko Yoshimura ,  Tomohisa Watanabe

    IPC: A61K39/00 ,  A61K31/7088 ,  C12N9/00 ,  C07K16/40 ,  G01N33/574

    Abstract: Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the UBE2T that elicit CTLs are provided. Isolated antigen-presenting cells with CTL inducibility and CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing such epitope peptides derived from UBE2T or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or the prevention of a postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the epitope peptides derived from UBE2T, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Patent Agency Ranking